| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c13d71aeae7bbca6aa10428f1afea9e0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
2021-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab5cc20ab764941e42eb46b75fe6f961
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b85683f7a1f72b7ddd59eed25408a772
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_687b2896fccad3e5b32d93c1241b15d6 |
| publicationDate |
2022-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022078354-A1 |
| titleOfInvention |
Use of ligustrazine nitrone compound in preparation of drug for preventing and/or treating renal anemia |
| abstract |
Disclosed in the present invention is the use of a ligustrazine nitrone compound in the preparation of a drug for preventing and/or treating renal anemia, wherein the ligustrazine nitrone compound is a compound having a structure as represented by general formula (I) or a pharmaceutically acceptable salt thereof. Experimental results show that the ligustrazine nitrone compound of the present invention can significantly increase the serum iron ion and erythropoietin content in STZ-induced SD rats and spontaneously hypertensive rats, and can be used for preventing and/or treating renal anemia caused by the decreased production of renal EPO or/and concomitant iron deficiency. Therefore, the ligustrazine nitrone compound can be prepared into various dosage forms with a drug carrier. |
| priorityDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |